Proteomics and metabolomics in inflammatory bowel disease

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue 7, 2013, Pages 1076-1086

  Yau, Yunki ^a,b   Leong, Rupert W ^b,c   Zeng, Ming ^a   Wasinger, Valerie C ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ANZAC Research Institute   (Australia)

^c BANKSTOWN LIDCOMBE HOSPITAL   (Australia)

Author keywords

Crohn's disease; Inflammatory bowel disease; Mass spectrometry; Metabolomics; Proteomics; Ulcerative colitis

Indexed keywords

BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALGRANULIN; CALGRANULIN C; CARCINOEMBRYONIC ANTIGEN; CASPASE RECRUITMENT DOMAIN PROTEIN 15; FLAGELLIN ANTIBODY; FUNGUS ANTIBODY; INFLIXIMAB; INTEGRIN; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 6; LACTOFERRIN; LYMPHOTOXIN; MERCAPTOPURINE; MITOCHONDRIAL PROTEIN; NEUTROPHIL CYTOPLASMIC ANTIBODY; OUTER MEMBRANE PORIN C ANTIBODY; PLASMA PROTEIN; PROTEIN ANTIBODY; SACCHAROMYCES ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; AUTOINFLAMMATORY DISEASE; CROHN DISEASE; DISEASE ACTIVITY; ENTERITIS; ENTEROPATHOGENIC ESCHERICHIA COLI; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; ESCHERICHIA COLI; GENOMICS; HUMAN; LYMPHOCYTE ACTIVATION; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METABOLITE; METABOLOMICS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEOMICS; PROTON NUCLEAR MAGNETIC RESONANCE; T LYMPHOCYTE; TANDEM MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS; ULCERATIVE COLITIS;

EID: 84879426139     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12193     Document Type: Article

References (133)

1. Consortium TIHGS. International Consortium Completes Human Genome Project. 2003. Cited 14 December 2012. Available from URL: http://genomics.energy.gov
2. DeLisi C. Overview of human genome research. Basic Life Sci. 1988; 46: 5-10.
3. Cavanaugh JA, Callen DF, Wilson SR etal. Analysis of Australian Crohn's disease pedigrees refines the localization for susceptibility to inflammatory bowel disease on chromosome 16. Ann. Hum. Genet. 1998; 62 (Pt 4): 291-298.
4. Cho JH, Nicolae DL, Gold LH etal. Identification of novel susceptibility loci for inflammatory bowel disease on chromosomes 1p, 3q, and 4q: evidence for epistasis between 1p and IBD1. Proc. Natl. Acad. Sci. U.S.A. 1998; 95: 7502-7507.
5. Curran ME, Lau KF, Hampe J etal. Genetic analysis of inflammatory bowel disease in a large European cohort supports linkage to chromosomes 12 and 16. Gastroenterology 1998; 115: 1066-1071.
6. Hugot JP, Chamaillard M, Zouali H etal. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411: 599-603.
7. Ogura Y, Bonen DK, Inohara N etal. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411: 603-606.
8. Ohmen JD, Yang HY, Yamamoto KK etal. Susceptibility locus for inflammatory bowel disease on chromosome 16 has a role in Crohn's disease, but not in ulcerative colitis. Hum. Mol. Genet. 1996; 5: 1679-1683.
9. Satsangi J, Parkes M, Louis E etal. Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12. Nat. Genet. 1996; 14: 199-202.
10. Satsangi J, Welsh KI, Bunce M etal. Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease. Lancet 1996; 347: 1212-1217.
11. Schrattenholz A, Groebe K, Soskic V. Systems biology approaches and tools for analysis of interactomes and multi-target drugs. Methods Mol. Biol. 2010; 662: 29-58.
12. Joyner MJ, Pedersen BK. Ten questions about systems biology. J. Physiol. 2011; 589 (Pt 5): 1017-1030.
13. Weizman AV, Silverberg MS. Have genomic discoveries in inflammatory bowel disease translated into clinical progress? Curr. Gastroenterol. Rep. 2012; 14: 139-145.
14. Vaiopoulou A, Gazouli M, Theodoropoulos G etal. Current advantages in the application of proteomics in inflammatory bowel disease. Dig. Dis. Sci. 2012; 57: 2755-2764.
15. Kimball AB, Grant RA, Wang F etal. Beyond the blot: cutting edge tools for genomics, proteomics and metabolomics analyses and previous successes. Br. J. Dermatol. 2012; 166 (Suppl. 2): 1-8.
16. Tyers M, Mann M. From genomics to proteomics. Nature 2003; 422: 193-197.
17. Ideker T, Thorsson V, Ranish JA etal. Integrated genomic and proteomic analyses of a systematically perturbed metabolic network. Science 2001; 292: 929-934.
18. Tan KC, Ipcho SV, Trengove RD etal. Assessing the impact of transcriptomics, proteomics and metabolomics on fungal phytopathology. Mol. Plant Pathol. 2009; 10: 703-715.
19. Li X, Conklin L, Alex P. New serological biomarkers of inflammatory bowel disease. World J. Gastroenterol. 2008; 14: 5115-5124.
20. Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J. Clin. Invest. 2007; 117: 514-521.
21. Patti GJ, Yanes O, Siuzdak G. Innovation: metabolomics: the apogee of the omics trilogy. Nat. Rev. Mol. Cell Biol. 2012; 13: 263-269.
22. Iskandar HN, Ciorba MA. Biomarkers in inflammatory bowel disease: current practices and recent advances. Transl. Res. 2012; 159: 313-325.
23. Barcelo-Batllori S, Andre M, Servis C etal. Proteomic analysis of cytokine induced proteins in human intestinal epithelial cells: implications for inflammatory bowel diseases. Proteomics 2002; 2: 551-560.
24. Marchesi JR, Fatima Khan EH, Kochhar S etal. Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. J. Proteome Res. 2007; 6: 546-551.
25. Keshavarzian A, Price YE, Peters AM etal. Specificity of indium-111 granulocyte scanning and fecal excretion measurement in inflammatory bowel disease-an autoradiographic study. Dig. Dis. Sci. 1985; 30: 1156-1160.
26. Vucelic B, Krznaric Z, Sentic M etal. [Value of C-reactive protein in the evaluation of activity in ulcerative colitis and Crohn's disease]. Lijec. Vjesn. 1990; 112: 281-284. Vrijednost C-reaktivnog proteina u procjeni aktivnosti ulceroznog kolitisa i Crohnove bolesti.
27. Harries AD, Beeching NJ, Rogerson SJ etal. The platelet count as a simple measure to distinguish inflammatory bowel disease from infective diarrhoea. J. Infect. 1991; 22: 247-250.
28. Duchmann R, Kaiser I, Hermann E etal. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin. Exp. Immunol. 1995; 102: 448-455.
29. Meenan J, Spaans J, Grool TA etal. Altered expression of alpha 4 beta 7, a gut homing integrin, by circulating and mucosal T cells in colonic mucosal inflammation. Gut 1997; 40: 241-246.
30. Stallmach A, Giese T, Schmidt C etal. Cytokine/chemokine transcript profiles reflect mucosal inflammation in Crohn's disease. Int. J. Colorectal Dis. 2004; 19: 308-315.
31. Perlis RH. Translating biomarkers to clinical practice. Mol. Psychiatry 2011; 16: 1076-1087.
32. Bargen JA, Barker NW. Extensive arterial and venous thrombosis complicating chronic ulcerative colitis. Arch. Intern. Med. 1936; 58: 17-31.
33. Morowitz DA, Allen LW, Kirsner JB. Thrombocytosis in chronic inflammatory bowel disease. Ann. Intern. Med. 1968; 68: 1013-1021.
34. Talstad I, Rootwelt K, Gjone E. Thrombocytosis in ulcerative colitis and Crohn's disease. Scand. J. Gastroenterol. 1973; 8: 135-138.
35. Kehoe EL, Newcomer KL. Thromboembolic phenomena in ulcerative colitis. Two case reports. Arch. Intern. Med. 1964; 113: 711-715.
36. Lake AM, Stauffer JQ, Stuart MJ. Hemostatic alterations in inflammatory bowel disease: response to therapy. Am. J. Dig. Dis. 1978; 23: 897-902.
37. Antibodies and ulcerative colitis. Br. Med. J. 1961; 2: 227-228.
38. Broberger O, Perlmann P. Autoantibodies in human ulcerative colitis. J. Exp. Med. 1959; 110: 657-674.
39. Buchberger R. [Regional enteritis and Crohn's disease]. Bruns. Beitr. Klin. Chir. 1959; 199: 220-236.
40. Haferkamp O. [On productive inflammation in enteritis regionalis (Crohn)]. Beitr. Pathol. Anat. 1959; 121: 27-38.
41. Bendixen G, Jarnum S, Soltoft J etal. IgG and albumin turnover in Crohn's disease. Scand. J. Gastroenterol. 1968; 3: 481-489.
42. Weeke B, Bendixen G. Serum immunoglobulins and organ-specific, cellular hypersensitivity in ulcerative colitis and Crohn's disease. Acta Med. Scand. 1969; 186: 87-91.
43. Soltoft J, Jarnum S. Faecal proteolysis of albumin and IgG in Crohn's disease and ulcerative colitis. Digestion 1969; 2: 282-288.
44. Thayer WR Jr, Brown M, Sangree MH etal. Escherichia Coli O:14 and colon hemagglutinating antibodies in inflammatory bowel disease. Gastroenterology 1969; 57: 311-318.
45. Mitchell AB, Gill AM, Orchard RT etal. Carcinoembryonic antigen in patients suffering from ulcerative proctocolitis. Am. J. Dig. Dis. 1975; 20: 407-417.
46. Gardner RC, Feinerman AE, Kantrowitz PA etal. Serial carcinoembryonic antigen (CEA) blood levels in patients with ulcerative colitis. Am. J. Dig. Dis. 1978; 23: 129-133.
47. Rule AH, Goleski-Reilly C, Sachar DB etal. Circulating carcinoembryonic antigen (CEA): relationship to clinical status of patients with inflammatory bowel disease. Gut 1973; 14: 880-884.
48. Thompson WG, Gillies RR, Silver HK etal. Carcinoembryonic antigen and alpha 1-fetoprotein in ulcerative colitis and regional enteritis. Can. Med. Assoc. J. 1974; 110: 775-777.
49. Kruis W, Fateh-Mogadam A, Sandel P. Serum levels of beta 2-microglobulin: a new marker of activity in Crohn's disease. N. Engl. J. Med. 1979; 301: 1348.
50. Descos L, Andre C, Beorghia S etal. Serum levels of beta-2-microglobulin-a new marker of activity in Crohn's disease. N. Engl. J. Med. 1979; 301: 440-441.
51. Henderson CA, Greenlee L, Williams RC Jr etal. Characterization of anti-lymphocyte antibodies in inflammatory bowel disease. Scand. J. Immunol. 1976; 5: 837-844.
52. Strickland RG, Friedler EM, Henderson CA etal. Serum lymphocytotoxins in inflammatory bowel disease. Studies of frequency and specificity for lymphocyte subpopulations. Clin. Exp. Immunol. 1975; 21: 384-393.
53. Korsmeyer S, Strickland RG, Wilson ID etal. Serum lymphocytotoxic and lymphocytophilic antibody activity in inflammatory bowel disease. Gastroenterology 1974; 67: 578-583.
54. Nishida T, Miwa H, Yamamoto M etal. Bile acid absorption kinetics in Crohn's disease on elemental diet after oral administration of a stable-isotope tracer with chenodeoxycholic-11, 12-d2 acid. Gut 1982; 23: 751-757.
55. Dinarello CA. Interleukin-1. Dig. Dis. Sci. 1988; 33 (3 Suppl.): 25S-35S.
56. Satsangi J, Wolstencroft RA, Cason J etal. Interleukin 1 in Crohn's disease. Clin. Exp. Immunol. 1987; 67: 594-605.
57. MacDonald TT, Hutchings P, Choy MY etal. Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin. Exp. Immunol. 1990; 81: 301-305.
58. Foley N, Lambert C, McNicol M etal. An inhibitor of the toxicity of tumour necrosis factor in the serum of patients with sarcoidosis, tuberculosis and Crohn's disease. Clin. Exp. Immunol. 1990; 80: 395-399.
59. Murch SH, Lamkin VA, Savage MO etal. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 1991; 32: 913-917.
60. Maeda M, Watanabe N, Neda H etal. Serum tumor necrosis factor activity in inflammatory bowel disease. Immunopharmacol. Immunotoxicol. 1992; 14: 451-461.
61. Braegger CP, Nicholls S, Murch SH etal. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992; 339: 89-91.
62. Stronkhorst A, Tytgat GN, van Deventer SJ. CD4 antibody treatment in Crohn's disease. Scand. J. Gastroenterol. Suppl. 1992; 194: 61-65.
63. Quinton JF, Sendid B, Reumaux D etal. Anti-saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1998; 42: 788-791.
64. Landers CJ, Cohavy O, Misra R etal. Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. Gastroenterology 2002; 123: 689-699.
65. Targan SR, Landers CJ, Yang H etal. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology 2005; 128: 2020-2028.
66. de Jong NS, Leach ST, Day AS. Fecal S100A12: a novel noninvasive marker in children with Crohn's disease. Inflamm. Bowel Dis. 2006; 12: 566-572.
67. Sugi K, Saitoh O, Hirata I etal. Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Am. J. Gastroenterol. 1996; 91: 927-934.
68. Saxon A, Shanahan F, Landers C etal. A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J. Allergy Clin. Immunol. 1990; 86: 202-210.
69. Ruemmele FM, Targan SR, Levy G etal. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology 1998; 115: 822-829.
70. Rump JA, Scholmerich J, Gross V etal. A new type of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn's disease. Immunobiology 1990; 181: 406-413.
71. Foell D, Kucharzik T, Kraft M etal. Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut 2003; 52: 847-853.
72. Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand. J. Gastroenterol. 1999; 34: 50-54.
73. Cohavy O, Harth G, Horwitz M etal. Identification of a novel mycobacterial histone H1 homologue (HupB) as an antigenic target of pANCA monoclonal antibody and serum immunoglobulin A from patients with Crohn's disease. Infect. Immun. 1999; 67: 6510-6517.
74. Sutton CL, Kim J, Yamane A etal. Identification of a novel bacterial sequence associated with Crohn's disease. Gastroenterology 2000; 119: 23-31.
75. Zholudev A, Zurakowski D, Young W etal. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Am. J. Gastroenterol. 2004; 99: 2235-2241.
76. Elitsur Y, Lawrence Z, Tolaymat N. The diagnostic accuracy of serologic markers in children with IBD: the West Virginia experience. J. Clin. Gastroenterol. 2005; 39: 670-673.
77. Dubinsky MC, Lin YC, Dutridge D etal. Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression. Am. J. Gastroenterol. 2006; 101: 360-367.
78. Jaskowski TD, Litwin CM, Hill HR. Analysis of serum antibodies in patients suspected of having inflammatory bowel disease. Clin. Vaccine Immunol. 2006; 13: 655-660.
79. Papp M, Altorjay I, Norman GL etal. Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients. Inflamm. Bowel Dis. 2007; 13: 984-992.
80. Nisihara RM, de Carvalho WB, Utiyama SR etal. Diagnostic role and clinical association of ASCA and ANCA in Brazilian patients with inflammatory bowel disease. Dig. Dis. Sci. 2010; 55: 2309-2315.
81. Hardwidge PR, Rodriguez-Escudero I, Goode D etal. Proteomic analysis of the intestinal epithelial cell response to enteropathogenic Escherichia coli. J. Biol. Chem. 2004; 279: 20127-20136.
82. Hsieh SY, Shih TC, Yeh CY etal. Comparative proteomic studies on the pathogenesis of human ulcerative colitis. Proteomics 2006; 6: 5322-5331.
83. Weichart D, Gobom J, Klopfleisch S etal. Analysis of NOD2-mediated proteome response to muramyl dipeptide in HEK293 cells. J. Biol. Chem. 2006; 281: 2380-2389.
84. Shkoda A, Werner T, Daniel H etal. Differential protein expression profile in the intestinal epithelium from patients with inflammatory bowel disease. J. Proteome Res. 2007; 6: 1114-1125.
85. Meuwis MA, Fillet M, Geurts P etal. Biomarker discovery for inflammatory bowel disease, using proteomic serum profiling. Biochem. Pharmacol. 2007; 73: 1422-1433.
86. Meuwis MA, Fillet M, Lutteri L etal. Proteomics for prediction and characterization of response to infliximab in Crohn's disease: a pilot study. Clin. Biochem. 2008; 41: 960-967.
87. Nanni P, Parisi D, Roda G etal. Serum protein profiling in patients with inflammatory bowel diseases using selective solid-phase bulk extraction, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and chemometric data analysis. Rapid Commun. Mass Spectrom. 2007; 21: 4142-4148.
88. Nanni P, Mezzanotte L, Roda G etal. Differential proteomic analysis of HT29 Cl.16E and intestinal epithelial cells by LC ESI/QTOF mass spectrometry. J. Proteomics 2009; 72: 865-873.
89. M'Koma AE, Seeley EH, Washington MK etal. Proteomic profiling of mucosal and submucosal colonic tissues yields protein signatures that differentiate the inflammatory colitides. Inflamm. Bowel Dis. 2011; 17: 875-883.
90. Cooney JM, Barnett MP, Brewster D etal. Proteomic analysis of colon tissue from interleukin-10 gene-deficient mice fed polyunsaturated Fatty acids with comparison to transcriptomic analysis. J. Proteome Res. 2012; 11: 1065-1077.
91. Presley LL, Ye J, Li X etal. Host-microbe relationships in inflammatory bowel disease detected by bacterial and metaproteomic analysis of the mucosal-luminal interface. Inflamm. Bowel Dis. 2012; 18: 409-417.
92. Murdoch TB, Fu H, MacFarlane S etal. Urinary metabolic profiles of inflammatory bowel disease in interleukin-10 gene-deficient mice. Anal. Chem. 2008; 80: 5524-5531.
93. Martin FP, Rezzi S, Philippe D etal. Metabolic assessment of gradual development of moderate experimental colitis in IL-10 deficient mice. J. Proteome Res. 2009; 8: 2376-2387.
94. Schicho R, Nazyrova A, Shaykhutdinov R etal. Quantitative metabolomic profiling of serum and urine in DSS-induced ulcerative colitis of mice by (1)H NMR spectroscopy. J. Proteome Res. 2010; 9: 6265-6273.
95. Ooi M, Nishiumi S, Yoshie T etal. GC/MS-based profiling of amino acids and TCA cycle-related molecules in ulcerative colitis. Inflamm. Res. 2011; 60: 831-840.
96. Shiomi Y, Nishiumi S, Ooi M etal. GCMS-based metabolomic study in mice with colitis induced by dextran sulfate sodium. Inflamm. Bowel Dis. 2011; 17: 2261-2274.
97. Baur P, Martin FP, Gruber L etal. Metabolic phenotyping of the Crohn's disease-like IBD etiopathology in the TNF (DeltaARE/WT) mouse model. J. Proteome Res. 2011; 10: 5523-5535.
98. Schicho R, Shaykhutdinov R, Ngo J etal. Quantitative metabolomic profiling of serum, plasma, and urine by (1)H NMR spectroscopy discriminates between patients with inflammatory bowel disease and healthy individuals. J. Proteome Res. 2012; 11: 3344-3357.
99. Stephens NS, Siffledeen J, Su X etal. Urinary NMR metabolomic profiles discriminate inflammatory bowel disease from healthy. J. Crohns Colitis 2013; 7: e42-48.
100. Leong RW, Gearry RB, Sparrow MP. Thiopurine hepatotoxicity in inflammatory bowel disease: the role for adding allopurinol. Expert Opin. Drug Saf. 2008; 7: 607-616.
101. Baker M. In biomarkers we trust? Nat. Biotechnol. 2005; 23: 297-304.
102. De Backer P, De Waele D, Van Speybroeck L. Ins and outs of systems biology vis-a-vis molecular biology: continuation or clear cut? Acta Biotheor. 2010; 58: 15-49.
103. Zhou B, Wang J, Ressom HW. MetaboSearch: tool for mass-based metabolite identification using multiple databases. PLoS ONE 2012; 7: e40096.
104. Wasinger VC, Cordwell SJ, Cerpa-Poljak A etal. Progress with gene-product mapping of the mollicutes: mycoplasma genitalium. Electrophoresis 1995; 16: 1090-1094.
105. Bonetta L. Protein-protein interactions: interactome under construction. Nature 2010; 468: 851-854.
106. Wasinger V. Holistic biology of microorganisms: genomics, transcriptomics, and proteomics. Methods Biochem. Anal. 2006; 49: 3-14.
107. Naylor S, Chen JY. Unraveling human complexity and disease with systems biology and personalized medicine. Per. Med. 2010; 7: 275-289.
108. Thelen JJ, Miernyk JA. The proteomic future: where mass spectrometry should be taking us. Biochem. J. 2012; 444: 169-181.
109. Seo J, Jeong J, Kim YM etal. Strategy for comprehensive identification of post-translational modifications in cellular proteins, including low abundant modifications: application to glyceraldehyde-3-phosphate dehydrogenase. J. Proteome Res. 2008; 7: 587-602.
110. Han X, Gross RW. Global analyses of cellular lipidomes directly from crude extracts of biological samples by ESI mass spectrometry: a bridge to lipidomics. J. Lipid Res. 2003; 44: 1071-1079.
111. Vieth M, Higgs RE, Robertson DH etal. Kinomics-structural biology and chemogenomics of kinase inhibitors and targets. Biochim. Biophys. Acta 2004; 1697: 243-257.
112. Gronow S, Brade H. Lipopolysaccharide biosynthesis: which steps do bacteria need to survive? J. Endotoxin Res. 2001; 7: 3-23.
113. Tweeddale H, Notley-McRobb L, Ferenci T. Effect of slow growth on metabolism of Escherichia coli, as revealed by global metabolite pool ("metabolome") analysis. J. Bacteriol. 1998; 180: 5109-5116.
114. Griffiths WJ, Koal T, Wang Y etal. Targeted metabolomics for biomarker discovery. Angew. Chem. Int. Ed Engl. 2010; 49: 5426-5445.
115. Arakaki AK, Skolnick J, McDonald JF. Marker metabolites can be therapeutic targets as well. Nature 2008; 456: 443.
116. Yanes O, Tautenhahn R, Patti GJ etal. Expanding coverage of the metabolome for global metabolite profiling. Anal. Chem. 2011; 83: 2152-2161.
117. Rappaport SM. Biomarkers intersect with the exposome. Biomarkers 2012; 17: 483-489.
118. Nicholson JK, Foxall PJ, Spraul M etal. 750MHz 1H and 1H-13C NMR spectroscopy of human blood plasma. Anal. Chem. 1995; 67: 793-811.
119. Holtta M, Zetterberg H, Mirgorodskaya E etal. Peptidome analysis of cerebrospinal fluid by LC-MALDI MS. PLoS ONE 2012; 7: e42555.
120. Wasinger V, Ly L, Fitzgerald A etal. Prefractionation, enrichment, desalting and depleting of low volume and low abundance proteins and peptides using the MF10. Methods Mol. Biol. 2008; 424: 257-275.
121. Ly L, Wasinger VC. Peptide enrichment and protein fractionation using selective electrophoresis. Proteomics 2008; 8: 4197-4208.
122. Ly L, Wasinger VC. Mass and charge selective protein fractionation for the differential analysis of T-cell and CD34+ stem cell proteins from cord blood. J. Proteomics 2010; 73: 571-578.
123. Nanni P, Levander F, Roda G etal. A label-free nano-liquid chromatography-mass spectrometry approach for quantitative serum peptidomics in Crohn's disease patients. J. Chromatogr. B. Analyt Technol Biomed Life Sci. 2009; 877: 3127-3136.
124. Nesvizhskii AI, Aebersold R. Interpretation of shotgun proteomic data: the protein inference problem. Mol. Cell. Proteomics 2005; 4: 1419-1440.
125. Schirbel A, Fiocchi C. Inflammatory bowel disease: established and evolving considerations on its etiopathogenesis and therapy. J. Dig. Dis. 2010; 11: 266-276.
126. Holmes E, Loo RL, Stamler J etal. Human metabolic phenotype diversity and its association with diet and blood pressure. Nature 2008; 453: 396-400.
127. Tsai WL, Chung RT. Viral hepatocarcinogenesis. Oncogene 2010; 29: 2309-2324.
128. Epel ES, Lin J, Wilhelm FH etal. Cell aging in relation to stress arousal and cardiovascular disease risk factors. Psychoneuroendocrinology 2006; 31: 277-287.
129. Hiemke C. Clinical utility of drug measurement and pharmacokinetics: therapeutic drug monitoring in psychiatry. Eur. J. Clin. Pharmacol. 2008; 64: 159-166.
130. Vineis P, Perera F. Molecular epidemiology and biomarkers in etiologic cancer research: the new in light of the old. Cancer Epidemiol. Biomarkers Prev. 2007; 16: 1954-1965.
131. Wild CP. Complementing the genome with an "exposome": the outstanding challenge of environmental exposure measurement in molecular epidemiology. Cancer Epidemiol. Biomarkers Prev. 2005; 14: 1847-1850.
132. Patel VR, Eckel-Mahan K, Sassone-Corsi P etal. CircadiOmics: integrating circadian genomics, transcriptomics, proteomics and metabolomics. Nat. Methods 2012; 9: 772-773.
133. Ansong C, Deatherage BL, Hyduke D etal. Studying Salmonellae and Yersiniae host-pathogen interactions using integrated 'omics and modeling. Curr. Top. Microbiol. Immunol. 2013; 363: 21-41.